Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | PDE6A | P16499 | 8/20 | 0.73 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970609 | 0.90 | PDE5A (0.81) | PDE5AKCNH2PDE6APDE11A | |
| SCHEMBL1971532 | 0.90 | PDE5A (1.00) | PDE5AKCNH2PDE6APDE11A | |
| SCHEMBL14390803 | 0.89 | PDE5A (0.79) | PDE5AKCNH2PDE6APDE11A | |
| Pf-03049423 SCHEMBL1969224 | 0.88 | PDE5A (1.00) | PDE5AKCNH2PDE6APDE11A | |
| Pf-03049423 SCHEMBL29357029 | 0.88 | PDE5A (1.00) | PDE5AKCNH2PDE6APDE11A | |
| Pf-03049423 SCHEMBL29766850 | 0.88 | PDE5A (1.00) | PDE5AKCNH2PDE6APDE11A | |
| SCHEMBL1973153 | 0.87 | PDE5A (1.00) | PDE5AKCNH2PDE6APDE11A | |
| SCHEMBL1970610 | 0.86 | PDE5A (1.00) | PDE5AKCNH2PDE6A | |
| SCHEMBL1970644 | 0.86 | PDE5A (0.84) | PDE5AKCNH2PDE6A | |
| SCHEMBL1970594 | 0.86 | PDE5A (1.00) | PDE5AKCNH2PDE6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013208-B1 | PYRIDIN[3,4-B]PYRAZINONES | PFIZER PROD INC (US) | 2011-06-22 | — | — | EP | claimed |
| US-7902195-B2 | Pyridine [3,4-b] pyrazinones | PHARMACIA & UPJOHN COMPANY LLC (US) | 2011-03-08 | — | — | US | claimed |
| EP-2013208-A1 | PYRIDIN[3,4-B]PYRAZINONES | Pfizer Products Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007122466-A1 | PYRIDINE[3,4-B]PYRAZINONES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | claimed |
| EP-2013208-B1 | PYRIDIN[3,4-B]PYRAZINONES | PFIZER PROD INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2013208-B1 | PYRIDIN[3,4-B]PYRAZINONES | PFIZER PROD INC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7902195-B2 | Pyridine [3,4-b] pyrazinones | PHARMACIA & UPJOHN COMPANY LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902195-B2 | Pyridine [3,4-b] pyrazinones | PHARMACIA & UPJOHN COMPANY LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902195-B2 | Pyridine [3,4-b] pyrazinones | PHARMACIA & UPJOHN COMPANY LLC (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2007122466-A1 | PYRIDINE[3,4-B]PYRAZINONES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | PFIZER INC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249615-A1 | Pyridine [3,4-b] Pyrazinones | CYP2B6, CYP2D6, CYP4B1 | PDE5A 608/4885KCNH2 411/4885PDE6A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.